Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.
Registro de base de conocimiento para la auditoría. Contenido clínico provisional: esto no es una prescripción. Un oncólogo debe verificar fuentes originales, aplicabilidad y estado de revisión.
Evidence for specific statements
These citations cover only the statements and scopes shown. They do not establish clinical approval of this record.
Bleomycin exposure warrants perioperative pulmonary-risk assessment. Label precautions favor lower oxygen concentrations, but observational evidence does not establish a universal FiO2 ceiling. Anesthesia should balance pulmonary risk with adequate oxygenation; a fixed limit must not cause inadequate oxygenation.
Perioperative oxygen management after bleomycin only; no verification of other BEP dosing or supportive-care statements.
SRC-BLEOMYCIN-US-LABEL SRC-AAKRE-BLEOMYCIN-PERIOPERATIVE-2014 SRC-BLEOMYCIN-OXYGEN-MONITORING-1984
Bleomycin label pulmonary adverse reactions; Aakre 2014 Results/Discussion; PMID 6200191 abstract.
Primary G-CSF prophylaxis is not universally required for metastatic testicular BEP; clinicians may choose it to maintain dose intensity. Supportive therapy follows individual assessment and institutional protocol.
G-CSF supportive-care selection only; no approval of anticancer dosing, renal adjustments or treatment eligibility.
SRC-EVIQ-TESTICULAR-BEP-320
eviQ 320 v9 treatment schedule footnote ** and supportive therapy defaults paragraph.
New cough or dyspnea during bleomycin treatment requires assessment for pulmonary toxicity; HRCT is preferred when toxicity is suspected. PFT/DLCO is adjunctive, is not a sole automatic stop rule and does not guarantee prevention of pulmonary toxicity.
Pulmonary symptom assessment and role of PFT/DLCO only; no blanket validation of other BEP claims.
SRC-BLEOMYCIN-UK-BEST-PRACTICE-2018
British Journal of Cancer best-practice guideline: role of PFTs and symptom monitoring sections.
BEP dose delays or reductions considered for kidney dysfunction require review by an experienced testicular-cancer centre because efficacy may be compromised. No universal cisplatin dose-reduction table or automatic switch to EP is established by this record.
Specialist review of kidney-related BEP dosing decisions only; no individualized dose prescription or blanket validation of other dose modifications.
SRC-EVIQ-TESTICULAR-BEP-320
eviQ 320 v9 Dose modifications: note on delays/reductions and renal dysfunction.
In the 1997 MRC/EORTC randomized study of good-risk metastatic nonseminomatous germ-cell cancer, the tested carboplatin-based CEB regimen was inferior to the tested cisplatin-based BEP regimen. This does not establish an alternative regimen for severe kidney impairment.
Comparative efficacy in the trial population and tested schedules only; not all germ-cell tumours, carboplatin indications or patients with severe kidney impairment.
SRC-HORWICH-BEP-CEB-1997
PMID 9164194 / DOI 10.1200/JCO.1997.15.5.1844: abstract Results and Conclusion.
Bleomycin unit systems must be identified explicitly. The eviQ equivalence is 1.5 USP units = 1500 International Units, so 30 USP units = 30000 International Units. US product vials are labelled 15 or 30 units of Bleomycin for Injection USP. Do not interpret milligram activity as a general mg-by-weight conversion.
Unit nomenclature and equivalence only; not individualized dosing, schedule selection, cumulative-risk elimination or whole-record clinical approval.
SRC-BLEOMYCIN-US-LABEL SRC-EVIQ-TESTICULAR-BEP-320
US label Description/How supplied; eviQ 320 treatment schedule bleomycin equivalence footnote.